Sai Parenterals acquiring majority stake in Bion

Sai Parenterals is acquiring a majority stake in Bion Therapeutics India in an all-cash deal to expand its presence in the domestic prescription market. The acquisition will integrate Bion's 16 brands into Sai Parenterals' manufacturing facilities to improve quality and margins.
Why it matters
This consolidation reflects ongoing trends in the Indian pharmaceutical sector to move from contract manufacturing to integrated, in-house production.
HYDERABAD Sai Parenterals, through subsidiary SP Analytics, is acquiring a majority stake in Hyderabad-based branded formulations prescription business company Bion Therapeutics India for an undisclosed sum. It will be an all-cash deal and a definitive agreement to acquire the stake has been signed. On completion, which is expected by this month, Bion will become a step-down subsidiary, Sai Parenterals said on Tuesday. The acquisition will add 16 established brands and around 250 field staff, strengthening its presence in India’s prescription market, Sai Parenterals said. Further, its manufacturing capability would create value addition to Bion. Bion’s portfolio is manufactured from contract manufacturers across several locations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in